Log in

Intellipharmaceutics International Stock Forecast, Price & News

-0.01 (-7.27 %)
(As of 10/21/2020 12:48 PM ET)
Today's Range
Now: $0.19
50-Day Range
MA: $0.13
52-Week Range
Now: $0.19
Volume27,205 shs
Average Volume105,774 shs
Market Capitalization$4.50 million
P/E RatioN/A
Dividend YieldN/A
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Read More
Intellipharmaceutics International logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$3.48 million
Book Value($0.17) per share


Net Income$-8,090,000.00
Net Margins-232.11%


Market Cap$4.50 million
Next Earnings Date2/26/2021 (Estimated)
-0.01 (-7.27 %)
(As of 10/21/2020 12:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPCIF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCIF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intellipharmaceutics International (OTCMKTS:IPCIF) Frequently Asked Questions

How has Intellipharmaceutics International's stock price been impacted by Coronavirus?

Intellipharmaceutics International's stock was trading at $0.1201 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPCIF shares have increased by 58.2% and is now trading at $0.19.
View which stocks have been most impacted by COVID-19

When is Intellipharmaceutics International's next earnings date?

Intellipharmaceutics International is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Intellipharmaceutics International

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) issued its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.70). The firm earned $0.58 million during the quarter, compared to analysts' expectations of $0.90 million.
View Intellipharmaceutics International's earnings history

When did Intellipharmaceutics International's stock split? How did Intellipharmaceutics International's stock split work?

Intellipharmaceutics International's stock reverse split on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of Intellipharmaceutics International stock prior to the reverse split would have 10 shares after the split.

Are investors shorting Intellipharmaceutics International?

Intellipharmaceutics International saw a increase in short interest in September. As of September 30th, there was short interest totaling 2,200 shares, an increase of 340.0% from the September 15th total of 500 shares. Based on an average trading volume of 23,900 shares, the days-to-cover ratio is currently 0.1 days.
View Intellipharmaceutics International's Short Interest

Who are some of Intellipharmaceutics International's key competitors?

Who are Intellipharmaceutics International's key executives?

Intellipharmaceutics International's management team includes the following people:
  • Dr. Isa Odidi M.B.A., Ph.D., MBA, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 62, Pay $455.71k)
  • Dr. Amina Odidi, Pres, COO, Co-Chief Scientific Officer, Acting CFO & Director (Age 60, Pay $455.71k)
  • Fazayill Shaideen, Controller

What is Intellipharmaceutics International's stock symbol?

Intellipharmaceutics International trades on the OTCMKTS under the ticker symbol "IPCIF."

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellipharmaceutics International's stock price today?

One share of IPCIF stock can currently be purchased for approximately $0.19.

How big of a company is Intellipharmaceutics International?

Intellipharmaceutics International has a market capitalization of $4.50 million and generates $3.48 million in revenue each year. Intellipharmaceutics International employs 33 workers across the globe.

What is Intellipharmaceutics International's official website?

The official website for Intellipharmaceutics International is www.intellipharmaceutics.com.

How can I contact Intellipharmaceutics International?

Intellipharmaceutics International's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.